Most Shorted Stocks
TXG is part of our most shorted stocks screen list, indicating it has a high short interest.
10X GENOMICS INC-CLASS A (TXG) Stock Price & Overview
NASDAQ:TXG • US88025U1097
Current stock price
24.91 USD
+1.33 (+5.64%)
Last:
The current stock price of TXG is 24.91 USD. Today TXG is up by 5.64%. In the past month the price increased by 25.49%. In the past year, price increased by 213.98%.
TXG Key Statistics
52-Week Range7.25 - 24.3
Current TXG stock price positioned within its 52-week range.
1-Month Range15.9 - 24.3
Current TXG stock price positioned within its 1-month range.
- Market Cap
- 3.182B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.43
- Dividend Yield
- N/A
TXG Stock Performance
Today
+5.64%
1 Week
+7.72%
1 Month
+25.49%
3 Months
+14.91%
Longer-term
6 Months +99.32%
1 Year +213.98%
2 Years -19.47%
3 Years -55.03%
5 Years -88.08%
10 Years N/A
TXG Stock Chart
TXG Stock Screens
TXG currently appears in the following ChartMill screener lists.
TXG Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TXG. When comparing the yearly performance of all stocks, TXG is one of the better performing stocks in the market, outperforming 96.53% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TXG Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TXG. TXG has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TXG Earnings
On February 12, 2026 TXG reported an EPS of -0.13 and a revenue of 166.03M. The company beat EPS expectations (39.41% surprise) and beat revenue expectations (3.21% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.13
Revenue Reported166.03M
EPS Surprise 39.41%
Revenue Surprise 3.21%
TXG Forecast & Estimates
22 analysts have analysed TXG and the average price target is 20.69 USD. This implies a price decrease of -16.94% is expected in the next year compared to the current price of 24.91.
For the next year, analysts expect an EPS growth of -127.32% and a revenue growth -3.5% for TXG
Analysts
Analysts72.73
Price Target20.69 (-16.94%)
EPS Next Y-127.32%
Revenue Next Year-3.5%
TXG Groups
Sector & Classification
TXG Financial Highlights
Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 71.71% compared to the year before.
Income Statements
Revenue(TTM)642.82M
Net Income(TTM)-43.54M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.18% | ||
| ROE | -5.47% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%67.5%
Sales Q2Q%0.61%
EPS 1Y (TTM)71.71%
Revenue 1Y (TTM)5.25%
TXG Ownership
Ownership
Inst Owners107.08%
Shares127.75M
Float115.45M
Ins Owners1.84%
Short Float %13.88%
Short Ratio6.35
TXG Competitors/Peers
The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.29 | 191.026B | ||
| DHR | DANAHER CORP | 23.5 | 138.617B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 145.35 | 45.438B | ||
| A | AGILENT TECHNOLOGIES INC | 17.94 | 33.206B | ||
| WAT | WATERS CORP | 22.81 | 31.851B | ||
| IQV | IQVIA HOLDINGS INC | 13.67 | 28.872B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.95 | 27.254B | ||
| ILMN | ILLUMINA INC | 24.73 | 19.412B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 32.72 | 18.738B | ||
| MEDP | MEDPACE HOLDINGS INC | 29.57 | 14.315B | ||
| RVTY | REVVITY INC | 17.17 | 10.357B | ||
| TECH | BIO-TECHNE CORP | 26.99 | 9.001B | ||
| CRL | CHARLES RIVER LABORATORIES | 16.3 | 8.799B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TXG
Company Profile
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Company Info
IPO: 2019-09-12
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588 US
CEO: Serge Saxonov
Employees: 1178
Phone: 13026587581
10X GENOMICS INC-CLASS A / TXG FAQ
Can you describe the business of 10X GENOMICS INC-CLASS A?
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
What is the stock price of 10X GENOMICS INC-CLASS A today?
The current stock price of TXG is 24.91 USD. The price increased by 5.64% in the last trading session.
Does TXG stock pay dividends?
TXG does not pay a dividend.
What is the ChartMill rating of 10X GENOMICS INC-CLASS A stock?
TXG has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is TXG stock listed?
TXG stock is listed on the Nasdaq exchange.
Would investing in 10X GENOMICS INC-CLASS A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TXG.